Guardion Launches VectorVision CSV-2000 Standardized Contrast Sensitivity Test
September 03 2019 - 7:00AM
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(Nasdaq: GHSI) announced that it has completed development of its
proprietary CSV-2000 standardized contrast sensitivity test and
will introduce the commercial product at Vision Expo West, a
conference for ophthalmic professionals, in Las Vegas, Nevada, from
September 18 to 21, 2019. The CSV-2000 is the only
computer-generated vision testing instrument available that will
provide the optical marketplace with the Company’s proprietary,
industry-standard contrast sensitivity test, along with a full
suite of standard vision testing protocols. The proprietary
standardization methodology incorporated into the CSV-2000 includes
a patented technology known as AcQviz that automatically and
constantly measures and adjusts screen luminance to a fixed
standard light level for vision testing.
Michael Favish, Guardion’s Chief Executive
Officer, commenting on the launch of this next generation of vision
testing technology, stated, “The VectorVision CSV-2000 represents a
paradigm shift in the accuracy and consistency of vision testing.
This technology will allow doctors to more accurately and
consistently quantify when treatment is needed and then document
outcomes related to various therapies. The introduction of this
technology extends Guardion’s leadership in the diagnosis and
monitoring of vision changes related to eye disease.”
About Guardion Health Sciences,
Inc.
Guardion is an ocular health sciences company
that develops, formulates and distributes condition-specific
medical foods supported by evidence-based protocols, with an
initial medical food product, Lumega-Z®, that addresses a depleted
macular protective pigment, a known risk factor for age-related
macular degeneration (“AMD”) and a significant component of
functional vision performance. Guardion Health Sciences, Inc. has
also developed a proprietary medical device, the MapcatSF®, which
accurately measures the macular pigment density, therefore
providing the only two-pronged evidence-based protocol for the
treatment of a depleted macular protective pigment. Information and
risk factors with respect to Guardion and its business, including
its ability to successfully develop and commercialize its
proprietary products and technologies, may be obtained in the
Company’s filings with the Securities and Exchange Commission
(“SEC”) at www.sec.gov.
About
VectorVision®
VectorVision®, operating through a wholly-owned
subsidiary of the Company, specializes in the standardization of
contrast sensitivity, glare sensitivity, low contrast acuity, and
ETDRS acuity vision testing. Its patented standardization system
provides the practitioner or researcher the ability to delineate
very small changes in visual capability, either as compared to the
population or from visit to visit. VectorVision®’s CSV-1000 device
is considered the standard of care for clinical trials.
Forward-Looking Statement
Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. These statements
involve unknown risks and uncertainties that may individually or
materially impact the matters discussed herein for a variety of
reasons that are outside the control of the Company, including, but
not limited to, the Company’s ability to raise sufficient financing
to implement its business plan and its ability to successfully
develop and commercialize its proprietary products and
technologies. Readers are cautioned not to place undue reliance on
these forward-looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s filings with the SEC, which are available at
the SEC’s website (www.sec.gov). The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Company Contact: |
|
Investor Relations Contact: |
|
|
|
Michael Favish |
|
Matthew Abenante |
|
|
|
Chief Executive Officer |
|
Porter, LeVay & Rose,
Inc. |
|
|
|
Telephone: (858) 605-9055 x
201 |
|
Telephone: (212) 564-4700 |
|
|
|
E-mail:
mfavish@guardionhealth.com |
|
E-mail:
matthew@plrinvest.com |
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Sep 2023 to Sep 2024